Oncology News

ESMO oncology news ensures that you're always kept up to date with the latest developments that affect you and your daily practice. Make sure you check these pages frequently, or sign up to our newsletter.

Filter

Date Title Topic
10 Sep 2017 ESMO 2017: Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment for Advanced or Metastatic RCC Genitourinary cancers - Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Ramucirumab Improves PFS in Patients with Platinum Refractory Advanced Urothelial Carcinoma Genitourinary cancers - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Combined Abemaciclib with NSAI Show Significant Clinical Benefit as Initial Treatment for Patients with HR-positive/HER2-negative ABC at Interim Analysis Breast cancer - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Biomarker Analysis Reveals Different Genes are Upregulated After Lenvatinib and Sorafenib Treatment in Unresected HCC Gastrointestinal cancers - Translational research
10 Sep 2017 ESMO 2017: Biosimilar Rituximab Shows Equivalent Efficacy to Reference Rituximab in Previously Untreated Advanced Follicular Lymphoma Haematologic malignancies - Anticancer agents & Biologic therapy
10 Sep 2017 ESMO 2017: Patients Receiving Radioactive Iodine for Well-Differentiated Thyroid Cancer Have an Increased Risk of AML Haematologic malignancies
10 Sep 2017 ESMO 2017: Strong Association Exists Between Tumour Type and Survival in Early Breast Cancer Breast cancer
10 Sep 2017 ESMO 2017: Genomic Landscape of Patients with TNBC and Disease Recurrence Investigated Breast cancer - Translational research
10 Sep 2017 ESMO 2017 Press Release: Mature Results Favour Pembrolizumab As Second-line Treatment For Bladder Cancer Genitourinary cancers
10 Sep 2017 ESMO 2017 Press Release: Licensing and Reimbursement Discrepancies Impact Patient Access to Cancer Treatment
10 Sep 2017 ESMO 2017 Press Release: Abemaciclib Initial Therapy Improves Outcome in Endocrine-sensitive Advanced Breast Cancer Breast cancer
10 Sep 2017 ESMO 2017 Press Release: Abdominal Fat a Key Cancer Driver for Postmenopausal Women
10 Sep 2017 ESMO 2017 Press Release: Ramucirumab plus Docetaxel Improves Progression-free survival in Urothelial Cancer Genitourinary cancers
10 Sep 2017 ESMO 2017 Press Release: Combination Immunotherapy in Second/third Line Extends Mesothelioma Survival to 15 Months Lung and other thoracic tumours
10 Sep 2017 ESMO 2017 Press Release: Study Shows ESMO Magnitude of Benefit Scale Can Be Used to Grade Orphan Drugs